<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016111930964N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-12-30</date_registration>
      <primary_sponsor>Vice Chancellor for research and technology of Ahvaz Jundishapur University of Medical Sciences</primary_sponsor>
      <public_title>Study of two non-invasive ventilation methods in the treatment of acute respiratory distress syndrome of infants</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of continuous positive oscillatory nasal airway pressure versus continuous positive nasal airway pressure in neonates with 28-34 weeks of gestational age with respiratory distress syndrome: A randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-06-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>128</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/24453</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Randomized based on a random number table.</study_design>
      <phase>3</phase>
      <hc_freetext>respiratory distress syndrome in new borns.</hc_freetext>
      <i_freetext>Intervention 1: Intervention 1: Eligible newborns were randomly allocated to the ‘Oscillatory NCPAP’ group. For this purpose, cno ncpap device ( made in Germany) was employed. Using this device, nasal continuous positive airway pressure with vibration was given to the patient. INSURE (intubation, surfactant treatment and extubation) technique would have been used if the patient had needed PEEP ≥5 cm/H2o and Fio2 ≥ 40%. The orogastric tube was kept open and suspended from the top wall of the incubator to decompress the stomach. Pulse oximeter saturation, respiratory rate and heart rate were continuously monitored. Blood pressure was measured at least every 6 hours. ABG was performed after 30 min of starting respiratory support, then, at least every 6 hours  in first 24 hours and every 8 hours in next 24 h and as indicated. We used oscillatory NCPAP with PEEP 4-6 cm of water, fraction of inspired oxygen (Fio2) of 0.4, frequency of 3 HZ and amplitude of 3 cm H2O. Maximum permissible PEEP was 8 cm and maximum permissible Fio2 was 0.6. Maximum permissible frequency and amplitude were at the time that we observed oscillation on chest wall (Maximum frequency of 5 HZ and amplitude of 7 cm H2O). Settings was adjusted based on arterial blood gases (ABG) and clinical parameters. Targeted saturation was ≥ 90 %. Intervention 2: Intervention 2: Eligible newborns were randomly allocated to the ‘NCPAP’ group. For this purpose, sindi ncpap device (made in Germany) was employed. Using this device, nasal continuous positive airway pressure was given to the patient. INSURE (intubation, surfactant treatment and extubation) technique would have been used if the patient had needed PEEP ≥5 cm/H2o and Fio2 ≥ 40%. The orogastric tube was kept open and suspended from the top wall of the incubator to decompress the stomach. Pulse oximeter saturation, respiratory rate and heart rate were continuously monitored. Blood pressure measured at least every 6 h. ABG was performed after 30 min of starting respiratory support, then, at least every 6 h in first 24 h and every 8 h in next 24 h and as indicated. We used NCPAP with PEEP equal to 4-6 cm of water and fraction of inspired oxygen (Fio2) equal to 0.4. Maximum permissible target was 8 cm for PEEP and 0.6 for Fio2. Settings was adjusted based on arterial blood gases (ABG) and clinical parameters. Targeted saturation was ≥ 90 %.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shiva Bashirnejad khabaz</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>The main door of Ahvaz Jundishapur University of Medical Sciences and Health Services, opposite the Khuzestan Water and Electricity Authority (five storeys), Golestan highway, Ahvaz</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1579461357</zip>
        <telephone>+98 613367543</telephone>
        <email>bashirnejad.sh@ajums.ac.ir; sh.bashirnejad@gmail.com</email>
        <affiliation>Ahvaz Jundishapur University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Arash Malekian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>The main door of Ahvaz Jundishapur University of Medical Sciences and Health Services, opposite the Khuzestan Water and Electricity Authority (five storeys), Golestan highway, Ahvaz</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6135715794</zip>
        <telephone>+98 613367543</telephone>
        <email>malekianarash@gmail.com</email>
        <affiliation>Ahvaz Jundishapur University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Preterm infants at gestational age of 28 to 34 weeks; weight between 1000 and 2000 grams; respiratory distress syndrome; Silverman-Anderson retraction score 6 - 7.&#13;
Exclusion criteria: Congenital malformation; cardiac disease; severe asphyxia (Apgar score ≤ 3 at 1 and 5 minute or pH ≤ 7.12); parents' unwillingness to participate in the study.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>1 day</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P22.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Respiratory distress syndrome of newborn</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention 1: Eligible newborns were randomly allocated to the ‘Oscillatory NCPAP’ group. For this purpose, cno ncpap device ( made in Germany) was employed. Using this device, nasal continuous positive airway pressure with vibration was given to the patient. INSURE (intubation, surfactant treatment and extubation) technique would have been used if the patient had needed PEEP ≥5 cm/H2o and Fio2 ≥ 40%. The orogastric tube was kept open and suspended from the top wall of the incubator to decompress the stomach. Pulse oximeter saturation, respiratory rate and heart rate were continuously monitored. Blood pressure was measured at least every 6 hours. ABG was performed after 30 min of starting respiratory support, then, at least every 6 hours  in first 24 hours and every 8 hours in next 24 h and as indicated. We used oscillatory NCPAP with PEEP 4-6 cm of water, fraction of inspired oxygen (Fio2) of 0.4, frequency of 3 HZ and amplitude of 3 cm H2O. Maximum permissible PEEP was 8 cm and maximum permissible Fio2 was 0.6. Maximum permissible frequency and amplitude were at the time that we observed oscillation on chest wall (Maximum frequency of 5 HZ and amplitude of 7 cm H2O). Settings was adjusted based on arterial blood gases (ABG) and clinical parameters. Targeted saturation was ≥ 90 %.</i_keyword>
      <i_keyword>Intervention 2: Eligible newborns were randomly allocated to the ‘NCPAP’ group. For this purpose, sindi ncpap device (made in Germany) was employed. Using this device, nasal continuous positive airway pressure was given to the patient. INSURE (intubation, surfactant treatment and extubation) technique would have been used if the patient had needed PEEP ≥5 cm/H2o and Fio2 ≥ 40%. The orogastric tube was kept open and suspended from the top wall of the incubator to decompress the stomach. Pulse oximeter saturation, respiratory rate and heart rate were continuously monitored. Blood pressure measured at least every 6 h. ABG was performed after 30 min of starting respiratory support, then, at least every 6 h in first 24 h and every 8 h in next 24 h and as indicated. We used NCPAP with PEEP equal to 4-6 cm of water and fraction of inspired oxygen (Fio2) equal to 0.4. Maximum permissible target was 8 cm for PEEP and 0.6 for Fio2. Settings was adjusted based on arterial blood gases (ABG) and clinical parameters. Targeted saturation was ≥ 90 %.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Non-invasive ventilatory failure. Timepoint: During first 72 hours of birth. Method of measurement: A questionnaire was used to investigate the noninvasive ventilation failure within first 72 hours of birth in which data were collected based on observation and ABG. The failure criteria were met by at least 1 of the following: pH ≤ 7.20 and PaCO2 ≥ 60 mm Hg, PaO2 ≤ 50 mm Hg with a fraction of inspired oxygen ≥ 0.6 or respiratory distress increase, recurrent apnea with ≥ 3 episodes per hour associated with bradycardia, a single episode of apnea that required bag and mask ventilation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Milk intolerance rate. Timepoint: Within admission period. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Pneumothorax. Timepoint: Within first 72 h. Method of measurement: CXR.</sec_outcome>
      <sec_outcome>IVH. Timepoint: At the end of first and fourth week or at the time of symptom incidence. Method of measurement: brain sonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for research and technology of Ahvaz Jundishapur University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-06-05</approval_date>
        <contact_name>Ethics committee, Ahvaz Jundishapur University of Medical Sciences</contact_name>
        <contact_address>The main door of Ahvaz Jundishapur University of Medical Sciences and Health Services, opposite the Khuzestan Water and Electricity Authority (five storeys), Golestan highway, Ahvaz Ahvaz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
